Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose radiolabeled somapacitan absorption, metabolism, and excretion study in healthy men
NL-OMON42854Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of somapacitan in growth hormone deficiency (GHD), sponsored by Novo Nordisk. Primary endpoints: Total amount of [3H]-somapacitan related material excreted in urine, Total amount of [3H]-somapacitan related material excreted in faeces and 1 more. Started Nov 2016; status: active, not recruiting.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NL-OMON42854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42854.